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ARTICLE OPEN
Should the diagnosis of COPD be based on a single
spirometry test?
Tjard R Schermer1, Bas Robberts2, Alan J Crockett3, Bart P Thoonen1, Annelies Lucas4, Joke Grootens1, Ivo J Smeele5,
Cindy Thamrin6 and Helen K Reddel6
Clinical guidelines indicate that a chronic obstructive pulmonary disease (COPD) diagnosis is made from a single spirometry test.
However, long-term stability of diagnosis based on forced expiratory volume in 1 s over forced vital capacity (FEV1/FVC) ratio
has not been reported. In primary care subjects at risk for COPD, we investigated shifts in diagnostic category (obstructed/
non-obstructed). The data were from symptomatic 40+ years (ex-)smokers referred for diagnostic spirometry, with three spirometry
tests, each 12 ± 2 months apart. The obstruction was based on post-bronchodilator FEV1/FVC o lower limit of normal (LLN) and
o0.70 (ﬁxed ratio). A total of 2,352 subjects (54% male, post-bronchodilator FEV1 76.5% predicted) were studied. By LLN deﬁnition,
32.2% were obstructed at baseline, but 32.2% of them were no longer obstructed at years 1 and/or 2. By ﬁxed ratio, these ﬁgures
were 46.6 and 23.8%, respectively. Overall, 14.3% of subjects changed diagnostic category by 1 year and 15.4% by 2 years when
applying the LLN cut-off, and 15.1 and 14.6% by ﬁxed ratio. Change from obstructed to non-obstructed was more likely for patients
with higher body mass index (BMI) and baseline short-acting bronchodilator (SABA) users, and less likely for older subjects,
those with lower FEV1% predicted, baseline inhaled steroid users, and current smokers or SABA users at year 1. Change from
non-obstructed to obstructed was more likely for males, older subjects, current smokers and patients with lower baseline FEV1%
predicted, and less likely for those with higher baseline BMI. Up to one-third of symptomatic (ex-)smokers with baseline obstruction
on diagnostic spirometry had shifted to non-obstructed when routinely re-tested after 1 or 2 years. Given the implications for
patients and health systems of a diagnosis of COPD, it should not be based on a single spirometry test.
npj Primary Care Respiratory Medicine (2016) 26, 16059; doi:10.1038/npjpcrm.2016.59; published online 29 September 2016
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a prevalent
chronic respiratory condition that is usually progressive and
associated with an enhanced chronic inﬂammatory response in
the airways and lungs to inhaled particles or gases.1 Current
international clinical COPD guidelines state that spirometry is
required to make the diagnosis.1–4 These guidelines state that the
presence of a post-bronchodilator forced expiratory volume in 1 s
(FEV1) over forced vital capacity (FVC) ratio below 0.70 conﬁrms
the presence of airway obstruction in subjects who are suspected
of having COPD due to cumulative exposure to risk factors
(e.g., tobacco smoke, occupational or indoor air pollution) and
presence of respiratory symptoms that are compatible with
COPD.1–4 There is increasing evidence that the use of an
age- and sex-speciﬁc lower limit of normal value for FEV1/FVC
would be a more appropriate approach when deﬁning airway
obstruction.5,6
In routine clinical practice, a COPD diagnosis is often based on a
single initial spirometry test, and none of the above COPD
guidelines recommend repeat spirometry testing when making
the diagnosis of COPD, or indicate that a different result may be
found if spirometry is repeated.1–4 Interestingly, although long-
term variability has been reported for FEV1 and FVC in healthy
subjects7–9 and for patients with COPD,10,11 and their year-to-year
variability is reported in ERS/ATS lung function guidelines to be
± 15%,12 similar evidence for variability of FEV1/FVC is lacking.
The aim of this study was, therefore, in a sample of subjects at
risk for COPD, to investigate the long-term stability of a diagnosis
on the basis of a once-only measurement of post-bronchodilator
FEV1/FVC ratio in primary care. We examined shifts in diagnostic
category (i.e., shifts between ‘obstructed’ and ‘non-obstructed’
and vice versa) after 1 year and 2 years. We used routine
spirometry data from subjects who had entered a respiratory
health diagnostic and annual monitoring service offered by
primary care diagnostic centres in the Netherlands.
RESULTS
Study subjects
Of 22,187 subjects in the databases, 2,352 fulﬁlled the inclusion
criteria (Figure 1). At baseline, airway obstruction was identiﬁed in
758 (32.2%) subjects by the LLN deﬁnition and in 1,097 (46.6%)
subjects by the ﬁxed FEV1/FVC deﬁnition. Table 1 shows baseline
characteristics for obstructed and non-obstructed subjects accord-
ing to the two deﬁnitions.
The average time between the initial diagnostic spirometry and
the ﬁrst follow-up measurement was 1.26 (s.d. 0.56) years, and
1.13 (s.d. 0.46) years between the ﬁrst and second follow-up
measurement.
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Agreement of obstruction status and FEV1/FVC values
Figure 2 shows the differences in post-BD FEV1/FVC between
T0 and T1, plotted against the baseline (T0) value. The coefﬁcient
of repeatability of the within-subject difference between two
consecutive FEV1/FVC measurements was 0.163 for the T0–T1 time
interval, 0.157 for the T1–T2 time interval and 0.176 for the T0–T2
time interval.
Figure 3 shows the shifts between diagnostic categories by LLN
(Figure 3a) and ﬁxed ratio criterion (Figure 3b). According to the LLN
criterion, 77.8% of subjects categorised as obstructed at baseline
were still categorised as having airway obstruction after 1 year, and
after 2 years only 67.8% had obstruction (Figure 3a). Figure 3a also
shows mean (s.d.) changes in FEV1, FVC and FEV1/FVC between T0
and T1 and between T1 and T2 in the respective categories. Of the
subjects without baseline airway obstruction (n=1,594), 90.1%
remained unobstructed after 1 year and 85.1% after 2 years.
Agreement between obstruction/non-obstruction status was
‘substantial’ when comparing T0 with T1 (Kappa=0.691, 95%
conﬁdence interval (95% CI) = 0.660–0.722) and T0 with T2
(Kappa=0.671, 95% CI= 0.640–0.702) classiﬁcations.
According to the ﬁxed FEV1/FVC deﬁnition, 83.0% of initially
obstructed subjects were still categorised as having airway
obstruction after 1 year, and after 2 years only 76.2% had
obstruction (Figure 3b). Of the subjects without baseline airway
obstruction (n= 1,255), 87.5% remained unobstructed after 1 year
and 81.3% after 2 years. Again, agreement between obstruction/
non-obstruction status was ‘substantial’ when comparing T0
with T1 (Kappa = 0.707, 95% CI = 0.678–0.736) and T0 with T2
(Kappa= 0.695, 95% CI = 0.666–0.724) classiﬁcations.
Figure 4 shows that diagnostic shifts were observed across the
full range of baseline FEV1/FVC values. Numbers (%) of patients
with borderline results in terms of the ﬁxed FEV1/FVC deﬁnition
(e.g., FEV1/FVC between 0.68 and 0.72) were 337 (14.3%) at T0, 319
(13.6%) at T1 and 321 (13.6%) at T2. Of the 315 patients who
shifted category in either direction between T0 and T1, only 65
(20.6%) were in the 0.68–0.72 range at T0.
Factors associated with shifting between diagnostic categories
Several factors were independently associated with shifting from
being obstructed at T0 to being non-obstructed at T1 when
applying the LLN FEV1/FVC criterion. Higher body mass index
(BMI) and baseline short-acting bronchodilator use increased the
odds of shifting to non-obstructed (Table 2). Older age, baseline
post-BD FEV1 o50% predicted, baseline inhaled corticosteroid
use, and being a current smoker or using a short-acting broncho-
dilator at T1 reduced this odds.
Being male, older age, lower baseline post-BD FEV1% predicted,
and being current smoker at baseline increased the odds of
shifting from being non-obstructed to being obstructed at T1,
whereas higher baseline BMI reduced these odds (Table 2).
Bronchodilator reversibility was not signiﬁcantly associated with
diagnostic shift in either direction.
DISCUSSION
Main Findings
In primary care, establishing the presence or absence of airway
obstruction when diagnosing COPD is often based on a single
spirometry test. This is consistent with clinical guidelines for the
diagnosis of COPD, which do not suggest that spirometry should
be repeated to conﬁrm the diagnosis. However, the short-term
and long-term stability of a decreased post-bronchodilator
FEV1/FVC ratio has not been reported. We investigated the shifts
between diagnostic categories after an initial spirometry test in
subjects for whom guidelines recommend investigation for COPD
(age ⩾ 40, current or ex-smoker, with respiratory symptoms) and
who were referred to a diagnostic service by their general
practitioner (GP). We found that, depending on the deﬁnition of
airway obstruction applied, after 1 year, 17–22% of subjects with
airway obstruction at baseline were no longer categorised as such,
and after 2 years, 24–32%; this shift was observed across a wide
range of baseline FEV1/FVC values. Of subjects without airway
obstruction at baseline, 10–13% were no longer non-obstructed
after 1 year, and 15–19% after 2 years. With Kappa values in the
range of 0.67–0.71 when comparing obstruction/non-obstruction
status at baseline and after 1 and 2 years, respectively, agreement
at a population level would be considered ‘substantial’, but the
implications for individual patients may be important. Gender,
age, BMI, post-BD FEV1% predicted, smoking status, and use of
short-acting bronchodilators and inhaled corticosteroids were
Figure 1. Selection of study subjects from the initial primary care diagnostic centres’ spirometry databases.
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associated with shifts between diagnostic categories in the logistic
regression models, but bronchodilator reversibility was not.
Interpretation of ﬁndings in relation to previously published work
It is well accepted that FEV1 and FVC vary over time in both
healthy persons and those with airways disease, with year-to-year
variability reported as ± 15% in the 2005 ATS/ERS guidelines for
lung function testing,12 and that bronchodilator reversibility in
patients with COPD varies when measured at 4-weekly intervals.13
However, the extent to which the FEV1/FVC ratio itself varies does
not appear to have been documented. In a secondary analysis of
the Lung Health Study dataset, which consists of 5-year follow-up
data from 5,321 current smokers aged 35–60 years with mild-to-
moderate obstructive pulmonary disease (deﬁned at the time as
baseline FEV1/FVC ratio ⩽ 0.75 and FEV1 50–90% predicted),14
Akkermans et al.15 observed that classiﬁcation as obstructed/non-
obstructed was inconsistent for 24% of Lung Health Study
participants between the initial screening and the ﬁrst follow-up
spirometry at 1 year. In another study examining the relationship
between baseline obstruction and lung function decline from the
present database, we noted that 36% of participants were
excluded as they had changed obstruction category during an
average of 3.4 years follow-up.16 However, we have not been able
to trace any other studies that have reported the short-term or
long-term consistency of a spirometric diagnosis of airway
obstruction in subjects with COPD-like symptoms.
Factors associated with diagnostic shift
Several factors were associated with shifting from obstructed to
non-obstructed over 1 year. Age was a signiﬁcant predictor of shift
Table 1. Baseline (T0) characteristics of the study sample (n= 2,352) for the two deﬁnitions of airway obstruction
LLN deﬁnition Fixed deﬁnition
Airway obstructiona
(n= 758)
No airway obstructiona
(n=1,594)
Airway obstructionb
(n=1,097)
No airway obstructionb
(n= 1,255)
Demographics
Age (years) 61.0 (10.2) 60.0 (10.8) 63.2 (10.2) 57.8 (10.3)
Males, n (%) 473 (62.4) 794 (49.8) 703 (64.1) 564 (44.9)
BMI (kg/m2) 26.1 (4.4) 27.7 (5.0) 26.4 (4.3) 28.0 (5.2)
Current smokers, n (%) 413 (54.5)c 649 (40.7)d 552 (50.3) 510 (40.6)
Lung function
FEV1 post-BD (L) 2.02 (0.64) 2.47 (0.71) 2.07 (0.64) 2.55 (0.70)
% Predicteda 64.9 (13.5) 82.0 (14.3) 67.9 (14.2) 84.0 (13.9)
⩾ 80%, n (%)e 103 (13.6) 878 (55.1) 223 (20.3) 758 (60.4)
50 to o80%, n (%)e 544 (71.8) 697 (43.7) 751 (68.5) 490 (39.0)
30 to o50%, n (%)e 107 (14.1) 18 (1.1) 118 (10.8) 7 (0.6)
o30%, n (%)e 4 (0.5) 1 (0.1) 5 (0.5) 0
FEV1 post-BD minus pre-BD, % (s.d.) 11.7 (11.6) 8.1 (8.4) 11.2 (11.1) 7.5 (7.9)
Reversiblef, n (%)e 271 (35.8) 380 (23.8) 371 (33.8) 280 (22.3)
FVC post-BD (L) 3.49 (0.98) 3.27 (0.92) 3.41 (0.97) 3.27 (0.92)
% Predicteda 87.3 (14.8) 84.6 (13.9) 86.7 (14.9) 84.4 (13.6)
FEV1/FVC post-BD 0.58 (0.08) 0.76 (0.07) 0.61 (0.08) 0.78 (0.05)
Respiratory medication
Any respiratory medication, n (%) 542 (71.5) 1216 (76.3) 771 (70.3) 987 (78.6)
Short-acting bronchodilator, n (%) 307 (40.5) 623 (39.1) 421 (38.4) 509 (40.6)
Long-acting bronchodilator, n (%) 296 (39.1) 586 (36.8) 416 (37.9) 466 (37.1)
Inhaled corticosteroid, n (%) 360 (47.5) 908 (57.0) 512 (46.7) 756 (60.2)
Exacerbationsg and respiratory symptomsh
Exacerbation(s) in past year, n (%) 301 (39.7) 633 (39.7) 431 (39.3) 503 (40.1)
Chronic cough, n (%) 474 (62.5) 800 (50.2) 637 (58.1) 639 (50.9)
Chronic sputum, n (%) 518 (68.3) 958 (60.1) 742 (67.6) 733 (58.4)
Daytime dyspnoea, n (%) 550 (72.5) 1097 (68.8) 769 (70.1) 876 (69.8)
Night-time dyspnoea, n (%) 129 (17.0) 330 (20.7) 189 (17.2) 272 (21.7)
Allergic symptoms, n (%) 236 (31.1) 666 (41.8) 331 (30.2) 572 (45.6)
Abbreviations: BD, bronchodilator; BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GLI, Global Lung Initiative;
GOLD: Global Initiative for Chronic Obstructive Lung Disease; LLN, lower limit of normal.
aBased on GLI reference equations.23
bBased on post-bronchodilator FEV1/FVC o0.70.
cSmoking status at T1: in smokers at baseline—83% still current smoker, 17% former smoker; in former smokers at baseline: 88% still former smoker,
12% current smoker.
dSmoking status at T1: in smokers at baseline—85% still current smoker, 15% former smoker; in former smokers at baseline: 94% still former smoker,
6% current smoker.
eGrouping of FEV1% predicted based on GOLD classiﬁcation of severity of airway obstruction.1
fReversibility: FEV1 ⩾ 12% and ⩾ 200 ml 15 min after 400 μg salbutamol administered by spacer.27
gExacerbations deﬁned as one or more self-reported episodes with aggravated respiratory symptoms lasting for several days in the past year.
hData on exacerbations and/or respiratory symptoms were missing in 676 of the 2,352 subjects (29%); therefore, these numbers and percentages are based on
1,676 subjects.
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(in either direction), even with the age-adjusted LLN criterion.
Other signiﬁcant predictors included male gender, lower baseline
FEV1% predicted and current smoking, all known predictors for
the development of COPD.17 Higher baseline BMI was signiﬁcantly
associated with shifts in both directions—increasing the prob-
ability of shifting from obstructed to non-obstructed, and
reducing the probability of shifting from non-obstructed to
obstructed. Baseline bronchodilator reversibility (which might
indicate greater underlying variability in lung function consistent
with asthma) was not associated with diagnostic shift in either
direction. Only limited information was available about medica-
tions, but use of inhaled corticosteroids at baseline appeared to
reduce the probability of shifting from obstructed to non-
obstructed.
Strengths and limitations of this study
Particular strengths of our study are the large sample of subjects
from primary care for whom guidelines recommend investigation
for COPD (respiratory symptoms, age ⩾ 40, smoker/ex-smoker),
the fact that all spirometry tests were performed by certiﬁed
technicians using standardised protocols and equipment,18 that
both pre- and post-bronchodilator spirometry were performed,
and the existence of regional primary care programmes for
ongoing monitoring of lung function as a part of routine
patient care.
The study has some limitations as well. First, we assume that the
patients being seen longitudinally in the primary care diagnostic
centres are representative of a larger population, but we have no
information on the precise reasons why some patients were
scheduled for annual follow-up visits, whereas other patients were
not. Selection may have occurred, as patients in the monitoring
service may have been patients of special concern to their GPs;
therefore, we cannot exclude the possibility that the number of
variable spirometric ﬁndings was falsely elevated because of this.
Also, patients with severe and unchanging disease may have been
referred to secondary care medical specialists and have been lost
to the primary care diagnostic centre monitoring service and,
consequently, to our dataset. This might have caused a bias away
from seeing consistent ﬁndings from year to year. Another
limitation of the study is the fact that, because these follow-up
visits are scheduled annually, we were not able to look at the
variability of FEV1/FVC over shorter periods of time—for instance,
within-day or week-to-week—as already reported for FEV1 and
FVC. Further research is needed to establish the optimal interval
between the initial spirometry test and a ‘veriﬁcation test’ after
some weeks or months. Clearly, regression to the mean effects
could have a role in explaining our observations as, by chance
alone, subjects with more extreme FEV1/FVC values are likely to
show less extreme values at reassessment; furthermore, as the
diagnosis of COPD is currently based on a speciﬁc FEV1/FVC value
(whether oLLN or ⩽ 0.70), trivial changes could lead to a
diagnostic shift for subjects with a baseline ratio just below or
just above the relevant cut-off point. However, only about 20% of
patients with a diagnostic shift had been in the borderline range
of 0.68–0.72 at baseline, and diagnostic shifts were observed
across the full range of baseline FEV1/FVC values (Figure 4). Finally,
subjects non-obstructed at baseline may have been less likely to
be enrolled in a diagnostic centre’s monitoring service and may
therefore be under-represented in our dataset.
In clinical practice, a COPD diagnosis is often based on a single
spirometry test. This is consistent with current guidelines, which
recommend that smoking or ex-smoking subjects aged ⩾ 40 years
with respiratory symptoms should be investigated for COPD and
that the diagnosis should be ‘based on spirometry’, with no
indication that it should be repeated to conﬁrm the diagnosis.
Given the importance of the FEV1/FVC ratio in making the
diagnosis of COPD, and the known year-to-year variability of FEV1
and FVC of ± 15%, we found it surprising that the variability of the
ratio does not appear to have been reported previously. The
current study shows that the FEV1/FVC ratio varies signiﬁcantly
over 1- and 2-year periods in subjects at a risk for COPD.
Depending on the criterion for obstruction that is applied, one-off
spirometry may lead to over- or under-diagnosis of COPD, and
either of these may have a signiﬁcant emotional impact on the
patient.19 Further, diagnostic inaccuracy will almost certainly lead
to over-treatment of some patients, with increased healthcare
Figure 2. Difference between FEV1/FVC values measured at baseline (T0) and after 1 year (T1), plotted against T0. The coefﬁcient of
repeatability of the difference between the FEV1/FVC measurements at T0 and T1 was 0.115. BD, bronchodilator; FEV1, forced expiratory
volume in 1 s; FVC, forced vital capacity; LLN, lower limit of normal.
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costs, increased risk for adverse effects and delay in identifying
other treatable causes of respiratory symptoms, whereas other
patients may be under-treated for COPD, contributing to
unnecessary burden of disease. Clinical COPD guidelines should
take this into account and recommend repetition of spirometry to
verify the presence or absence of airway obstruction. An
alternative view that has been increasingly heard in recent years
is that the diagnosis of a heterogeneous multi-system condition
such as COPD should not be based on a single number.6,20,21 This
is especially relevant for primary care, where the vast majority of
patients with early and mild COPD are diagnosed and treated.
Conclusions
Although overall agreement between baseline and repeated
diagnostic classiﬁcation of airway obstruction may be technically
Figure 3. Change in obstruction status between baseline, year 1 and year 2 in respiratory symptomatic smokers and ex-smokers aged 40+
years. (a) Based on post-bronchodilator FEV1/FVCo or ⩾ LLN. *Denominator for all proportions in the downstream cells. †Indicates
12± 2 months after previous test. BD, bronchodilator; FEV1, forced expiratory volume in 1 s (litres); FVC, forced vital capacity (litres); LLN, lower
limit of normal. ΔFEV1, ΔFVC and ΔFEV1/FVC calculated as T1 minus T0, and T2 minus T1, respectively and reported as mean (s.d.). (b) Based
on post-bronchodilator FEV1/FVCo or ⩾ 0.70.
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classiﬁed as ‘substantial’ at a population level, a key ﬁnding of the
present analysis was that up to one-third of people at risk for
COPD who were found to have airway obstruction when
referred for diagnostic spirometry by their GP had shifted to
non-obstructed when routinely re-tested after 1 or 2 years.
Similar shifts were seen with LLN and ﬁxed-ratio criteria. Gender,
age, BMI, baseline FEV1% predicted, smoking status and use of
respiratory medication were associated with the probability of
change in diagnostic category, but broncho-dilator reversibility
was not. Given the implications described above for patients
and the healthcare system, we do not believe that the diagnosis
of COPD should be based on a single spirometry test.
Figure 4. Probability of being non-obstructed after 1 year (T1) in relation to a subject’s post-BD FEV1/FVC at baseline T0. The graph shows
moving averages based on two consecutive data points (i.e., values for the probabilities in the actual FEV1/FVC bin and the next bin) to
‘smooth’ the curve. BD, bronchodilator; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
Table 2. Results from multivariable logistic regression models looking at factors associated with diagnostic shift between baseline (T0) and 1-year
measurements (T1) using post-BD lower limit of normal (LLN) FEV1/FVC cut-off points to deﬁne the presence or absence of airway obstruction
Determinant Shift from obstructed at baseline
to non-obstructed after 1 year
Shift from non-obstructed at
baseline to obstructed after 1 year
OR 95% CI P OR 95% CI P
Males (versus females) 0.81 0.55 1.20 0.288 1.41 0.96 2.05 0.077
Age (per year older) 0.98 0.96 1.00 0.069 1.03 1.01 1.04 0.006
BMI (per kg/m2 higher) 1.07 1.03 1.12 0.002 0.93 0.89 0.97 o0.001
Signiﬁcant bronchodilator reversibilitya (versus no signiﬁcant reversibility) 0.76 0.50 1.13 0.178 1.31 0.87 1.98 0.192
Post-BD FEV1 50 to o80% predicted (versus ⩾ 80% predicted) 0.66 0.39 1.10 0.113 2.94 1.96 4.39 o0.001
Post-BD FEV1 o50% predicted (versus ⩾ 80% predicted) 0.41 0.19 0.87 0.020 6.80 2.19 21.08 0.001
Current smoker at baselineb (versus former smokers) 1.12 0.62 2.02 0.694 3.43 1.53 7.66 0.003
Current smoker after 1 yearb (versus former smokers) 0.43 0.24 0.78 0.005 0.65 0.29 1.45 0.294
Short-acting bronchodilatorc at baselineb (versus no short-acting BD) 1.58 0.95 2.61 0.076 1.38 0.84 2.27 0.207
Short-acting bronchodilatorc after 1 yearb (versus no short-acting BD) 0.61 0.37 1.01 0.053 0.74 0.45 1.21 0.229
Long-acting bronchodilatorb,d (versus no long-acting BD) 1.20 0.59 2.42 0.614 0.89 0.43 1.84 0.761
Long-acting bronchodilator after 1 yearb,d (versus no long-acting BD) 0.75 0.38 1.47 0.397 1.26 0.61 2.61 0.527
Inhaled corticosteroids at baselineb (versus no ICS) 0.56 0.30 1.05 0.069 0.78 0.48 1.26 0.312
Inhaled corticosteroids after 1 yearb (versus no ICS) 1.39 0.76 2.53 0.284 0.98 0.60 1.60 0.940
Odds ratios that are statistically signiﬁcantly different from 1 are printed in bold.
Abbreviations: BD, bronchodilator; BMI, body mass index; CI, conﬁdence interval; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ICS, inhaled
corticosteroids; LLN, lower limit of normal; OR, odds ratio.
aSigniﬁcant bronchodilator reversibility: increase in FEV1 ⩾ 12% and ⩾ 200 ml 15 min after 400 μg salbutamol administered by spacer.27
bInteraction terms for T0 and T1 values of smoking status, short-acting BD use, long-acting BD use and ICS use were not statistically signiﬁcant.
cShort-acting β2-agonists and/or anticholinergics.
dLong-acting β2-agonists and/or anticholinergics.
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MATERIALS AND METHODS
Study setting and measurements
This observational study was based on all available spirometry tests from
the period October 2001 to March 2010 from three regional primary care
diagnostic centres (i.e., General Practice Laboratory Foundation Etten-Leur/
Breda (SHL); Diagnostic Center Eindhoven (DC4U) and General Practice
Laboratory East (SHO)) in the Netherlands. These diagnostic centres have
offered a range of diagnostic tests, including spirometry, and other health
services to hundreds of GPs in the south-western and south-eastern parts
of the country since the mid- or late 1990s. When a subject consults his/her
GP with respiratory symptoms and the GP suspects an underlying chronic
respiratory condition (e.g., COPD or asthma), the subject can be referred to
the diagnostic centre for pre- and post-bronchodilator spirometry testing.
When a chronic respiratory condition is diagnosed or still suspected, the
GP will usually enrol the subject in the diagnostic centre’s routine
monitoring service for periodic (usually yearly) reassessment without
further clinical selection.
As previously reported,18 all spirometry tests in the primary care
diagnostic centres are performed by certiﬁed lung function technicians
using personal computer-based digital volume sensor spirometers
(SpiroPerfect; Welch Allyn, Delft, The Netherlands) and standardised
calibration and measurement procedures.18 Subjects are instructed to
withhold all bronchodilators before spirometry. The spirometry test results
and accompanying demographic (gender, age), anthropometric (height,
weight) and medical history information (including self-reported smoking
status and history, respiratory symptoms, respiratory medications and
exacerbations) are recorded during each visit using a standardised
electronic format. Every spirometry test is assessed by a respiratory
consultant and his/her interpretation and—if applicable—diagnostic
advice is sent to the GP, together with the actual test results. Further
details about the spirometry tests performed in the diagnostic centres are
described elsewhere.18 At the time, the diagnostic centres did not
electronically store spirometry test quality assessments in their databases.
As only routine lung function and respiratory medical history data were
used for our analyses and the investigators had no access to information
on subjects’ identity or their medical records, no written informed consent
was obtained.
Subject selection and deﬁnitions for airway obstruction
For the current study, we selected subjects from the combined primary
care diagnostic centres’ databases (n=22,187)16 who had risk factors for
COPD and had complete questionnaire data and follow-up spirometry. The
inclusion criteria were the following: being Caucasian; current or former
smoker; aged ⩾ 40 years; complete data regarding height, history of
cigarette smoking and respiratory medication use; and three or more
post-bronchodilator spirometry tests available with 12± 2 months
(10–14 months) between tests.
We used post-bronchodilator FEV1/FVC values to classify the subjects as
having or not having airway obstruction. The following two deﬁnitions of
airway obstruction were applied:
● LLN cut-off (primary deﬁnition): post-bronchodilator FEV1/FVC below the
subject’s age-speciﬁc lower limit of normal (LLN) value.22 Airway
obstruction was classiﬁed as being present when the resulting standard
deviation (s.d.) score (also known as ‘standardised z-score’) was
o − 1.645. This corresponds with the ﬁfth percentile.
● Fixed cut-off point (secondary deﬁnition): post-bronchodilator FEV1/FVC
o0.70. This is the criterion for airway obstruction that is still
recommended in clinical COPD guidelines.1–4
Global Lung Initiative prediction equations23 were used to calculate the
LLN values for FEV1/FVC and %predicted values for FEV1.
Analysis
Subjects were categorised as showing airway obstruction or not at their
consecutive measurements (baseline (T0), 1 year (T1) and 2 years (T2)). The
Kappa statistic and its 95% CI were calculated to express the level of
agreement between T0 and T1 and between T0 and T2 diagnostic status,
respectively. The following classiﬁcation in terms of strength of agreement
for the kappa coefﬁcient was used: Kappa ⩽ 0 = poor agreement; 0.01
to 0.20 = slight; 0.21 to 0.40 = fair; 0.41 to 0.60 =moderate; 0.61
to 0.80 = substantial; and 0.81 to 1 = almost perfect.24 A modiﬁed
Bland–Altman25 plot was generated to graphically express differences in
FEV1/FVC between T0 and T1, compared with the baseline (T0) value, and
the coefﬁcient of repeatability26 was calculated to express the within-
subject repeatability (or absolute reliability) of the two consecutive
FEV1/FVC measurements. The coefﬁcient of repeatability is the value
below which the absolute differences between two measurements would
lie with 0.95 probability. Both random and systematic errors are taken into
account in the coefﬁcient.26
In univariate analyses we calculated the probability of being (non-)
obstructed after 1 year in relation to a subject’s baseline post-
bronchodilator FEV1/FVC value. We also explored subject characteristics
that predicted shifting diagnostic category between T0 and T1 measure-
ments for the primary (LLN) deﬁnition of obstruction using multivariable
logistic regression models. Covariates in these analyses were gender, age
(at T0), BMI (at T0), severity of airway obstruction (categorised according to
GOLD as mild, moderate and (very) severe obstruction, based on %
predicted FEV1, at T0),
1 reversibility of obstruction (yes/no ΔFEV1 ⩾ 200 ml
and ⩾ 12%, at T0),27 smoking status (current smoker yes/no, at T0 and T1),
use of short-acting bronchodilators (yes/no, at T0 and T1), use of long-
acting bronchodilators (yes/no, at T0 and T1) and use of inhaled
corticosteroids (yes/no, at T0 and T1). The changes in smoking status,
short-acting bronchodilator use, long-acting bronchodilator use, and
inhaled corticosteroid use were expressed in the models using interaction
terms of the respective T0 and T1 covariates, but dropped at a later stage
as they were not statistically signiﬁcant. Separate models were constructed
for each of the two possible directions of shifting (i.e., from obstructed to
non-obstructed or vice versa). Associations were expressed as odds ratios
with 95% CIs. Tests were two-sided. Po0.10 was considered statistically
signiﬁcant. IBM SPSS Statistics Version 22 (Armonk, NY, USA) was used for
the analyses.
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